Analysis of Assortiment of Medicines for the Treatment of Benign Prostate Diseases for the Evaluation of Particular Marketing Opportunities for Domestic Manufacturers

ScienceRise: Pharmaceutical Science
doi 10.15587/2519-4852.2017.93892
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Private Company Technology Center

Related search

Endoscopic Ablation for Benign Enlargement of the Prostate

BMJ
2008English

Economic Evaluation of Treatment for Benign Prostatic Hyperplasia

Japanese Journal of Urology
Urology
2002English

Developing New Medicines for the Treatment of Pain

Prescriber
Pharmacology
2019English

Exploring Uncertainty in Economic Evaluation of Medicines: A Review of the First Manufacturers' Submissions to the French National Authority for Health (Has)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Herbal Medicines for the Treatment of Inflammatory Bowel Disease

Cochrane Database of Systematic Reviews
2014English

Pharmacovigilance of Medicines for Rare and Ultrarare Diseases

Therapeutic Advances in Drug Safety
Pharmacology
2018English

Analysis of the Risk Factors for Incidental Carcinoma of the Prostate in Patients With Benign Prostatic Hyperplasia

Clinics
Medicine
2006English

Fosfomycin for the Treatment of Prostate Infection

Internal Medicine
Internal MedicineMedicine
2014English

Modern Opportunities for the Treatment of Chronic Prostatitis

Andrologia i Genital'naa Hirurgia
SurgeryReproductive MedicineUrology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy